chromosome 20 control probe targeting the centromeric region Search Results


c dna probes oligonucleotide primers  (Thermo Fisher)
99
Thermo Fisher c dna probes oligonucleotide primers
C Dna Probes Oligonucleotide Primers, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/chromosome+20+control+probe+targeting+the+centromeric+region/10__1042_slash_bj2910701-27-9-18?v=Thermo+Fisher
Average 99 stars, based on 1 article reviews
c dna probes oligonucleotide primers - by Bioz Stars, 2026-07
99/100 stars
  Buy from Supplier
dense chromosome 20 array  (NimbleGen Systems GmbH)
90
NimbleGen Systems GmbH dense chromosome 20 array
Dense Chromosome 20 Array, supplied by NimbleGen Systems GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/chromosome+20+control+probe+targeting+the+centromeric+region/pmc04716680-84-15-27?v=NimbleGen+Systems+GmbH
Average 90 stars, based on 1 article reviews
dense chromosome 20 array - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
fluorescently labeled dna probes  (LGC Biosearch)
90
LGC Biosearch fluorescently labeled dna probes
Fluorescently Labeled Dna Probes, supplied by LGC Biosearch, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/chromosome+20+control+probe+targeting+the+centromeric+region/pm36268933-228-0-25?v=LGC+Biosearch
Average 90 stars, based on 1 article reviews
fluorescently labeled dna probes - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
chromosome 20 α satellite  (Valiant Co Ltd)
99
Valiant Co Ltd chromosome 20 α satellite
Detection of bladder cancer cells in voided urine by FISH with a probe specific for AURKA. A) Dual-fluorescence FISH with probes for AURKA (red) and the <t>chromosome</t> <t>20</t> α-satellite DNA (green). Nuclei were counterstained with DAPI (blue); (first panel) normal urothelial cell; (second panel) a low-grade (grades 1–2) transitional cell carcinoma (TCC) cell; (third panel) a high-grade (grade 3) invasive TCC cell; (fourth panel) a high-grade (grade 3) invasive TCC cell. B) Quantitative FISH analysis of AURKA gene copy number in voided urine specimens from 23 patients with TCC of the bladder whose urine samples were included in the training set. The percentage of cells with low (3–4 copies) and high (>4 copies) amplification of AURKA in the individual patients is shown. C) Mean percentage of cells with 3–4 copies of AURKA and >4 copies of AURKA in low-grade (grades 1–2) superficial (Ta–T1a) and high-grade (grade 3) invasive (T1b or higher) TCCs. Two-sided P value for a two-sample t test comparing the mean percentage of cells with 3–4 copies of AURKA and 4 copies of AURKA in low-grade (grades 1–2) superficial (Ta–T1a) and high-grade (grade 3) invasive (T1b or higher) TCCs is shown. D) Receiver operating characteristic (ROC) curve for AURKA FISH test in the training set, which consisted of 23 urine samples from patients with bladder cancer and 7 urine samples from healthy unaffected control subjects (n = 30). The AURKA FISH test for the detection of bladder cancer showed an area under the receiver operating characteristic curve (AUC) of 0.997 (95% confidence interval [CI] = 0.984 to 1.000). P value was calculated from two-sided Wilcoxon–Mann–Whitney rank sum test statistics. E) ROC curve for AURKA FISH test in the test set, which consisted of 100 urine samples from patients with bladder cancer and 148 urine samples from healthy unaffected control subjects (n = 92) and patients with benign urological disorders (n = 56). The AURKA FISH test showed an AUC of 0.939 (95% CI = 0.906 to 0.971). P < .001 (two-sided Wilcoxon–Mann–Whitney rank sum test statistics). F) AURKA gene score for the training and testing sets by histological grade of TCC stratified into low (grades 1–2) and high (grade 3) groups. Horizontal bars designate the mean AURKA gene score for TCCs of low and high histological grade. P value was calculated from two-sided Mann–Whitney t test.
Chromosome 20 α Satellite, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/chromosome+20+control+probe+targeting+the+centromeric+region/pmc02720731-128-20-32?v=Valiant+Co+Ltd
Average 99 stars, based on 1 article reviews
chromosome 20 α satellite - by Bioz Stars, 2026-07
99/100 stars
  Buy from Supplier
snp c1orf167 c 1202883 20  (Thermo Fisher)
95
Thermo Fisher snp c1orf167 c 1202883 20
Detection of bladder cancer cells in voided urine by FISH with a probe specific for AURKA. A) Dual-fluorescence FISH with probes for AURKA (red) and the <t>chromosome</t> <t>20</t> α-satellite DNA (green). Nuclei were counterstained with DAPI (blue); (first panel) normal urothelial cell; (second panel) a low-grade (grades 1–2) transitional cell carcinoma (TCC) cell; (third panel) a high-grade (grade 3) invasive TCC cell; (fourth panel) a high-grade (grade 3) invasive TCC cell. B) Quantitative FISH analysis of AURKA gene copy number in voided urine specimens from 23 patients with TCC of the bladder whose urine samples were included in the training set. The percentage of cells with low (3–4 copies) and high (>4 copies) amplification of AURKA in the individual patients is shown. C) Mean percentage of cells with 3–4 copies of AURKA and >4 copies of AURKA in low-grade (grades 1–2) superficial (Ta–T1a) and high-grade (grade 3) invasive (T1b or higher) TCCs. Two-sided P value for a two-sample t test comparing the mean percentage of cells with 3–4 copies of AURKA and 4 copies of AURKA in low-grade (grades 1–2) superficial (Ta–T1a) and high-grade (grade 3) invasive (T1b or higher) TCCs is shown. D) Receiver operating characteristic (ROC) curve for AURKA FISH test in the training set, which consisted of 23 urine samples from patients with bladder cancer and 7 urine samples from healthy unaffected control subjects (n = 30). The AURKA FISH test for the detection of bladder cancer showed an area under the receiver operating characteristic curve (AUC) of 0.997 (95% confidence interval [CI] = 0.984 to 1.000). P value was calculated from two-sided Wilcoxon–Mann–Whitney rank sum test statistics. E) ROC curve for AURKA FISH test in the test set, which consisted of 100 urine samples from patients with bladder cancer and 148 urine samples from healthy unaffected control subjects (n = 92) and patients with benign urological disorders (n = 56). The AURKA FISH test showed an AUC of 0.939 (95% CI = 0.906 to 0.971). P < .001 (two-sided Wilcoxon–Mann–Whitney rank sum test statistics). F) AURKA gene score for the training and testing sets by histological grade of TCC stratified into low (grades 1–2) and high (grade 3) groups. Horizontal bars designate the mean AURKA gene score for TCCs of low and high histological grade. P value was calculated from two-sided Mann–Whitney t test.
Snp C1orf167 C 1202883 20, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/chromosome+20+control+probe+targeting+the+centromeric+region/pmc09415743-192-15-8?v=Thermo+Fisher
Average 95 stars, based on 1 article reviews
snp c1orf167 c 1202883 20 - by Bioz Stars, 2026-07
95/100 stars
  Buy from Supplier
chromosome enumeration probe cep20  (Chrombios GmbH)
90
Chrombios GmbH chromosome enumeration probe cep20
Detection of bladder cancer cells in voided urine by FISH with a probe specific for AURKA. A) Dual-fluorescence FISH with probes for AURKA (red) and the <t>chromosome</t> <t>20</t> α-satellite DNA (green). Nuclei were counterstained with DAPI (blue); (first panel) normal urothelial cell; (second panel) a low-grade (grades 1–2) transitional cell carcinoma (TCC) cell; (third panel) a high-grade (grade 3) invasive TCC cell; (fourth panel) a high-grade (grade 3) invasive TCC cell. B) Quantitative FISH analysis of AURKA gene copy number in voided urine specimens from 23 patients with TCC of the bladder whose urine samples were included in the training set. The percentage of cells with low (3–4 copies) and high (>4 copies) amplification of AURKA in the individual patients is shown. C) Mean percentage of cells with 3–4 copies of AURKA and >4 copies of AURKA in low-grade (grades 1–2) superficial (Ta–T1a) and high-grade (grade 3) invasive (T1b or higher) TCCs. Two-sided P value for a two-sample t test comparing the mean percentage of cells with 3–4 copies of AURKA and 4 copies of AURKA in low-grade (grades 1–2) superficial (Ta–T1a) and high-grade (grade 3) invasive (T1b or higher) TCCs is shown. D) Receiver operating characteristic (ROC) curve for AURKA FISH test in the training set, which consisted of 23 urine samples from patients with bladder cancer and 7 urine samples from healthy unaffected control subjects (n = 30). The AURKA FISH test for the detection of bladder cancer showed an area under the receiver operating characteristic curve (AUC) of 0.997 (95% confidence interval [CI] = 0.984 to 1.000). P value was calculated from two-sided Wilcoxon–Mann–Whitney rank sum test statistics. E) ROC curve for AURKA FISH test in the test set, which consisted of 100 urine samples from patients with bladder cancer and 148 urine samples from healthy unaffected control subjects (n = 92) and patients with benign urological disorders (n = 56). The AURKA FISH test showed an AUC of 0.939 (95% CI = 0.906 to 0.971). P < .001 (two-sided Wilcoxon–Mann–Whitney rank sum test statistics). F) AURKA gene score for the training and testing sets by histological grade of TCC stratified into low (grades 1–2) and high (grade 3) groups. Horizontal bars designate the mean AURKA gene score for TCCs of low and high histological grade. P value was calculated from two-sided Mann–Whitney t test.
Chromosome Enumeration Probe Cep20, supplied by Chrombios GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/chromosome+20+control+probe+targeting+the+centromeric+region/pm19648887-64-38-44?v=Chrombios+GmbH
Average 90 stars, based on 1 article reviews
chromosome enumeration probe cep20 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
copy number variation uty mm00527143 cn  (Thermo Fisher)
85
Thermo Fisher copy number variation uty mm00527143 cn
Detection of bladder cancer cells in voided urine by FISH with a probe specific for AURKA. A) Dual-fluorescence FISH with probes for AURKA (red) and the <t>chromosome</t> <t>20</t> α-satellite DNA (green). Nuclei were counterstained with DAPI (blue); (first panel) normal urothelial cell; (second panel) a low-grade (grades 1–2) transitional cell carcinoma (TCC) cell; (third panel) a high-grade (grade 3) invasive TCC cell; (fourth panel) a high-grade (grade 3) invasive TCC cell. B) Quantitative FISH analysis of AURKA gene copy number in voided urine specimens from 23 patients with TCC of the bladder whose urine samples were included in the training set. The percentage of cells with low (3–4 copies) and high (>4 copies) amplification of AURKA in the individual patients is shown. C) Mean percentage of cells with 3–4 copies of AURKA and >4 copies of AURKA in low-grade (grades 1–2) superficial (Ta–T1a) and high-grade (grade 3) invasive (T1b or higher) TCCs. Two-sided P value for a two-sample t test comparing the mean percentage of cells with 3–4 copies of AURKA and 4 copies of AURKA in low-grade (grades 1–2) superficial (Ta–T1a) and high-grade (grade 3) invasive (T1b or higher) TCCs is shown. D) Receiver operating characteristic (ROC) curve for AURKA FISH test in the training set, which consisted of 23 urine samples from patients with bladder cancer and 7 urine samples from healthy unaffected control subjects (n = 30). The AURKA FISH test for the detection of bladder cancer showed an area under the receiver operating characteristic curve (AUC) of 0.997 (95% confidence interval [CI] = 0.984 to 1.000). P value was calculated from two-sided Wilcoxon–Mann–Whitney rank sum test statistics. E) ROC curve for AURKA FISH test in the test set, which consisted of 100 urine samples from patients with bladder cancer and 148 urine samples from healthy unaffected control subjects (n = 92) and patients with benign urological disorders (n = 56). The AURKA FISH test showed an AUC of 0.939 (95% CI = 0.906 to 0.971). P < .001 (two-sided Wilcoxon–Mann–Whitney rank sum test statistics). F) AURKA gene score for the training and testing sets by histological grade of TCC stratified into low (grades 1–2) and high (grade 3) groups. Horizontal bars designate the mean AURKA gene score for TCCs of low and high histological grade. P value was calculated from two-sided Mann–Whitney t test.
Copy Number Variation Uty Mm00527143 Cn, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/chromosome+20+control+probe+targeting+the+centromeric+region/pmc04445009-177-28-39?v=Thermo+Fisher
Average 85 stars, based on 1 article reviews
copy number variation uty mm00527143 cn - by Bioz Stars, 2026-07
85/100 stars
  Buy from Supplier
dna probes  (Gen-Probe ltd)
90
Gen-Probe ltd dna probes
Detection of bladder cancer cells in voided urine by FISH with a probe specific for AURKA. A) Dual-fluorescence FISH with probes for AURKA (red) and the <t>chromosome</t> <t>20</t> α-satellite DNA (green). Nuclei were counterstained with DAPI (blue); (first panel) normal urothelial cell; (second panel) a low-grade (grades 1–2) transitional cell carcinoma (TCC) cell; (third panel) a high-grade (grade 3) invasive TCC cell; (fourth panel) a high-grade (grade 3) invasive TCC cell. B) Quantitative FISH analysis of AURKA gene copy number in voided urine specimens from 23 patients with TCC of the bladder whose urine samples were included in the training set. The percentage of cells with low (3–4 copies) and high (>4 copies) amplification of AURKA in the individual patients is shown. C) Mean percentage of cells with 3–4 copies of AURKA and >4 copies of AURKA in low-grade (grades 1–2) superficial (Ta–T1a) and high-grade (grade 3) invasive (T1b or higher) TCCs. Two-sided P value for a two-sample t test comparing the mean percentage of cells with 3–4 copies of AURKA and 4 copies of AURKA in low-grade (grades 1–2) superficial (Ta–T1a) and high-grade (grade 3) invasive (T1b or higher) TCCs is shown. D) Receiver operating characteristic (ROC) curve for AURKA FISH test in the training set, which consisted of 23 urine samples from patients with bladder cancer and 7 urine samples from healthy unaffected control subjects (n = 30). The AURKA FISH test for the detection of bladder cancer showed an area under the receiver operating characteristic curve (AUC) of 0.997 (95% confidence interval [CI] = 0.984 to 1.000). P value was calculated from two-sided Wilcoxon–Mann–Whitney rank sum test statistics. E) ROC curve for AURKA FISH test in the test set, which consisted of 100 urine samples from patients with bladder cancer and 148 urine samples from healthy unaffected control subjects (n = 92) and patients with benign urological disorders (n = 56). The AURKA FISH test showed an AUC of 0.939 (95% CI = 0.906 to 0.971). P < .001 (two-sided Wilcoxon–Mann–Whitney rank sum test statistics). F) AURKA gene score for the training and testing sets by histological grade of TCC stratified into low (grades 1–2) and high (grade 3) groups. Horizontal bars designate the mean AURKA gene score for TCCs of low and high histological grade. P value was calculated from two-sided Mann–Whitney t test.
Dna Probes, supplied by Gen-Probe ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/chromosome+20+control+probe+targeting+the+centromeric+region/10__1128_slash_jcm__39__9__3373___3375__2001-9-66-68?v=Gen-Probe+ltd
Average 90 stars, based on 1 article reviews
dna probes - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
chromosome 20 centromere probe cep20  (Abbott Laboratories)
86
Abbott Laboratories chromosome 20 centromere probe cep20
Figure 3 (A) Array-CGH profiles of chromosome 20 for case 5 (upper), showing gain in 20q11.2 and 20q13.12, and case 4 (below) with high-level amplification in 20q13.12. (B) FISH analysis of UBCH10 (green) and centromere 20 <t>(CEP20,</t> red) in normal metaphase and interphase nuclei, and in ATC cases 8, 9, and 3 with regional gain of UBCH10.
Chromosome 20 Centromere Probe Cep20, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/chromosome+20+control+probe+targeting+the+centromeric+region/10__1677_slash_erc___08___0018-54-33-61?v=Abbott+Laboratories
Average 86 stars, based on 1 article reviews
chromosome 20 centromere probe cep20 - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier
nuclease s1 reaction mix  (GE Healthcare)
93
GE Healthcare nuclease s1 reaction mix
Figure 3 (A) Array-CGH profiles of chromosome 20 for case 5 (upper), showing gain in 20q11.2 and 20q13.12, and case 4 (below) with high-level amplification in 20q13.12. (B) FISH analysis of UBCH10 (green) and centromere 20 <t>(CEP20,</t> red) in normal metaphase and interphase nuclei, and in ATC cases 8, 9, and 3 with regional gain of UBCH10.
Nuclease S1 Reaction Mix, supplied by GE Healthcare, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/chromosome+20+control+probe+targeting+the+centromeric+region/pm12542536-70-6-36?v=GE+Healthcare
Average 93 stars, based on 1 article reviews
nuclease s1 reaction mix - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier
aurka fish probe  (Applied Genetics Laboratories)
90
Applied Genetics Laboratories aurka fish probe
Figure 3 (A) Array-CGH profiles of chromosome 20 for case 5 (upper), showing gain in 20q11.2 and 20q13.12, and case 4 (below) with high-level amplification in 20q13.12. (B) FISH analysis of UBCH10 (green) and centromere 20 <t>(CEP20,</t> red) in normal metaphase and interphase nuclei, and in ATC cases 8, 9, and 3 with regional gain of UBCH10.
Aurka Fish Probe, supplied by Applied Genetics Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/chromosome+20+control+probe+targeting+the+centromeric+region/pmc02720731-113-5-34?v=Applied+Genetics+Laboratories
Average 90 stars, based on 1 article reviews
aurka fish probe - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
cdna  (OriGene)
90
OriGene cdna
Figure 3 (A) Array-CGH profiles of chromosome 20 for case 5 (upper), showing gain in 20q11.2 and 20q13.12, and case 4 (below) with high-level amplification in 20q13.12. (B) FISH analysis of UBCH10 (green) and centromere 20 <t>(CEP20,</t> red) in normal metaphase and interphase nuclei, and in ATC cases 8, 9, and 3 with regional gain of UBCH10.
Cdna, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/chromosome+20+control+probe+targeting+the+centromeric+region/pm27543612-46-4-20?v=OriGene
Average 90 stars, based on 1 article reviews
cdna - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

Image Search Results


Detection of bladder cancer cells in voided urine by FISH with a probe specific for AURKA. A) Dual-fluorescence FISH with probes for AURKA (red) and the chromosome 20 α-satellite DNA (green). Nuclei were counterstained with DAPI (blue); (first panel) normal urothelial cell; (second panel) a low-grade (grades 1–2) transitional cell carcinoma (TCC) cell; (third panel) a high-grade (grade 3) invasive TCC cell; (fourth panel) a high-grade (grade 3) invasive TCC cell. B) Quantitative FISH analysis of AURKA gene copy number in voided urine specimens from 23 patients with TCC of the bladder whose urine samples were included in the training set. The percentage of cells with low (3–4 copies) and high (>4 copies) amplification of AURKA in the individual patients is shown. C) Mean percentage of cells with 3–4 copies of AURKA and >4 copies of AURKA in low-grade (grades 1–2) superficial (Ta–T1a) and high-grade (grade 3) invasive (T1b or higher) TCCs. Two-sided P value for a two-sample t test comparing the mean percentage of cells with 3–4 copies of AURKA and 4 copies of AURKA in low-grade (grades 1–2) superficial (Ta–T1a) and high-grade (grade 3) invasive (T1b or higher) TCCs is shown. D) Receiver operating characteristic (ROC) curve for AURKA FISH test in the training set, which consisted of 23 urine samples from patients with bladder cancer and 7 urine samples from healthy unaffected control subjects (n = 30). The AURKA FISH test for the detection of bladder cancer showed an area under the receiver operating characteristic curve (AUC) of 0.997 (95% confidence interval [CI] = 0.984 to 1.000). P value was calculated from two-sided Wilcoxon–Mann–Whitney rank sum test statistics. E) ROC curve for AURKA FISH test in the test set, which consisted of 100 urine samples from patients with bladder cancer and 148 urine samples from healthy unaffected control subjects (n = 92) and patients with benign urological disorders (n = 56). The AURKA FISH test showed an AUC of 0.939 (95% CI = 0.906 to 0.971). P < .001 (two-sided Wilcoxon–Mann–Whitney rank sum test statistics). F) AURKA gene score for the training and testing sets by histological grade of TCC stratified into low (grades 1–2) and high (grade 3) groups. Horizontal bars designate the mean AURKA gene score for TCCs of low and high histological grade. P value was calculated from two-sided Mann–Whitney t test.

Journal: JNCI Journal of the National Cancer Institute

Article Title: Quantitation of Aurora Kinase A Gene Copy Number in Urine Sediments and Bladder Cancer Detection

doi: 10.1093/jnci/djn304

Figure Lengend Snippet: Detection of bladder cancer cells in voided urine by FISH with a probe specific for AURKA. A) Dual-fluorescence FISH with probes for AURKA (red) and the chromosome 20 α-satellite DNA (green). Nuclei were counterstained with DAPI (blue); (first panel) normal urothelial cell; (second panel) a low-grade (grades 1–2) transitional cell carcinoma (TCC) cell; (third panel) a high-grade (grade 3) invasive TCC cell; (fourth panel) a high-grade (grade 3) invasive TCC cell. B) Quantitative FISH analysis of AURKA gene copy number in voided urine specimens from 23 patients with TCC of the bladder whose urine samples were included in the training set. The percentage of cells with low (3–4 copies) and high (>4 copies) amplification of AURKA in the individual patients is shown. C) Mean percentage of cells with 3–4 copies of AURKA and >4 copies of AURKA in low-grade (grades 1–2) superficial (Ta–T1a) and high-grade (grade 3) invasive (T1b or higher) TCCs. Two-sided P value for a two-sample t test comparing the mean percentage of cells with 3–4 copies of AURKA and 4 copies of AURKA in low-grade (grades 1–2) superficial (Ta–T1a) and high-grade (grade 3) invasive (T1b or higher) TCCs is shown. D) Receiver operating characteristic (ROC) curve for AURKA FISH test in the training set, which consisted of 23 urine samples from patients with bladder cancer and 7 urine samples from healthy unaffected control subjects (n = 30). The AURKA FISH test for the detection of bladder cancer showed an area under the receiver operating characteristic curve (AUC) of 0.997 (95% confidence interval [CI] = 0.984 to 1.000). P value was calculated from two-sided Wilcoxon–Mann–Whitney rank sum test statistics. E) ROC curve for AURKA FISH test in the test set, which consisted of 100 urine samples from patients with bladder cancer and 148 urine samples from healthy unaffected control subjects (n = 92) and patients with benign urological disorders (n = 56). The AURKA FISH test showed an AUC of 0.939 (95% CI = 0.906 to 0.971). P < .001 (two-sided Wilcoxon–Mann–Whitney rank sum test statistics). F) AURKA gene score for the training and testing sets by histological grade of TCC stratified into low (grades 1–2) and high (grade 3) groups. Horizontal bars designate the mean AURKA gene score for TCCs of low and high histological grade. P value was calculated from two-sided Mann–Whitney t test.

Article Snippet: The first type of probe was a commercially available dual-color FISH probe that was designed to detect AURKA gene and chromosome 20 α-satellite (ie, centromeric) DNA ( AURKA 20q13/α-satellite 20 DNA probe; MP Biomedicals/Qbiogene, Illkirch, France).

Techniques: Fluorescence, Amplification, MANN-WHITNEY

Figure 3 (A) Array-CGH profiles of chromosome 20 for case 5 (upper), showing gain in 20q11.2 and 20q13.12, and case 4 (below) with high-level amplification in 20q13.12. (B) FISH analysis of UBCH10 (green) and centromere 20 (CEP20, red) in normal metaphase and interphase nuclei, and in ATC cases 8, 9, and 3 with regional gain of UBCH10.

Journal: Endocrine Related Cancer

Article Title: Array-CGH identifies cyclin D1 and UBCH10 amplicons in anaplastic thyroid carcinoma

doi: 10.1677/erc-08-0018

Figure Lengend Snippet: Figure 3 (A) Array-CGH profiles of chromosome 20 for case 5 (upper), showing gain in 20q11.2 and 20q13.12, and case 4 (below) with high-level amplification in 20q13.12. (B) FISH analysis of UBCH10 (green) and centromere 20 (CEP20, red) in normal metaphase and interphase nuclei, and in ATC cases 8, 9, and 3 with regional gain of UBCH10.

Article Snippet: Fluorescence in situ hybridization (FISH) FISH analyses were performed on interphase imprints from frozen ATCs and on metaphase preparations of ATC cells using the BAC clone RP11-344G20 covering UBCH10 at 20q13.12 plus a chromosome 20 centromere probe (CEP20) as described previously (Lee et al. 2007), or pre-labeled probes for CCND1 and the chromosome 11 centromere (LSI CCND1 Spectrum Orange/CEP 11 SpectrumGreen1 Vysis, Inc., Downers Grove, IL, USA).

Techniques: